Shattuck Labs Announces Participation in Upcoming December Conferences
Shattuck Labs Announces Participation in Upcoming December Conferences
A live webcast of the presentation and fireside chat will be available on the Investors section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced that company management will participate in two investor conferences in December 2024.
德克薩斯州奧斯丁和北卡羅來納州達勒姆，2024年11月25日（環球新聞社）—— Shattuck Labs, Inc.（Shattuck）（納斯達克：STTK），一家在開發針對腫瘤壞死因子（TNF）超級家族受體的新型治療藥物方面首屈一指的生物技術公司，旨在治療癌症患者和慢性免疫相關疾病的患者，今天宣佈公司管理層將參加2024年12月的兩個投資者會議。
Presentation Details
Conference: Piper Sandler 36th Annual Healthcare Conference
Format: Corporate Presentation
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
Date: December 3, 2024
Time: 12:30 p.m. ET
報告詳情
會議：派傑投資第36屆年度醫療保健會議
格式：企業介紹
演講者：泰勒·施雷伯萬博士，Shattuck首席執行官
日期：2024年12月3日
時間：美東時間下午12:30
Conference: Evercore 7th Annual HealthCONx Conference
Format: Fireside chat with covering analyst, Jonathan Miller, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
Date: December 4, 2024
Time: 8:45 a.m. ET
會議：evercore第七屆年度HealthCONx會議
形式：與分析師Jonathan Miller博士的爐邊談話
演講者：Shattuck首席執行官Taylor Schreiber萬.D.博士
日期：2024年12月4日
時間：東部時間上午8:45
A live webcast of the presentation and fireside chat will be available on the Investors section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.
演講和爐邊談話的現場網絡直播將在公司網站的投資者部分提供。網絡直播的回放將在演講日期後保存長達90天。
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases and cancer. The Company is developing a potentially first-in-class antibody for the treatment of IBD and other inflammatory autoimmune diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: .
關於Shattuck labs，Inc。
shattuck labs, inc. (納斯達克: STTK)是一家專注於爲自身免疫/炎症性疾病和癌症開發潛在治療方案的生物技術公司。該公司正在開發一種可能成爲頭號抗體的治療IBD和其他炎症性自身免疫疾病的抗體。派傑投資在蛋白工程和創新TNF受體激動劑和拮抗劑治療藥物的開發方面的專業知識彙集到其主要項目SL-325中，這是一種首創性的DR3拮抗抗體，旨在實現臨床驗證的TL1A/DR3途徑更完全的阻斷。該公司在得克薩斯州奧斯汀和北卡羅萊納州達勒姆都設有辦公室。更多信息，請訪問:。
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
公司打算使用其網站的投資者關係部分作爲披露非公開信息的手段，並遵守《FD條例》下的披露義務。
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
投資者及媒體聯繫方式：
Conor Richardson
投資者關係副總裁
Shattuck labs，inc。
InvestorRelations@shattucklabs.com
譯文內容由第三人軟體翻譯。
